We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-26.78%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$765M
AUM Growth
-$373M
Cap. Flow
-$25.7M
Cap. Flow %
-3.36%
Top 10 Hldgs %
52.72%
Holding
58
New
1
Increased
22
Reduced
25
Closed
3

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$15.8M
2
KURA icon
Kura Oncology
KURA
+$10.1M
3
MRUS
Merus
MRUS
+$8.69M
4
VSTM icon
Verastem
VSTM
+$7.77M
5
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$7.27M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$26M
2
ARRY
Array Biopharma Inc
ARRY
+$23.5M
3
XNCR icon
Xencor
XNCR
+$8.96M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$7.76M
5
CYTK icon
Cytokinetics
CYTK
+$7.6M

Sector Composition

Rank Sector Weight
1 Healthcare 83.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FSTX
26
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$9.89M 1.29%
237,925
-400
-0.2% -$18K
REPL icon
27
Replimune Group
REPL
$905M
$9M 1.18%
899,617
-12,235
-1% -$165K
SNDX icon
28
Syndax Pharmaceuticals
SNDX
$1.69B
$8.85M 1.16%
1,987,669
+754,051
+61% +$4.13M
VBIV
29
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$8.35M 1.09%
173,895
+70,562
+68% +$3.87M
LITS
30
Lite Strategy Inc
LITS
$32.8M
$7.86M 1.03%
148,935
-5,080
-3% -$313K
ARGX icon
31
argenx
ARGX
$53.9B
$7.77M 1.02%
80,868
+4,060
+5% +$361K
CRVS icon
32
Corvus Pharmaceuticals
CRVS
$1.11B
$6.94M 0.91%
1,890,507
– –
EIGR
33
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6.86M 0.9%
+22,500
New +$7.27M
CDTX
34
DELISTED
Cidara Therapeutics
CDTX
$6.83M 0.89%
145,234
+48,700
+50% +$3.48M
IMDZ
35
DELISTED
Immune Design Corp.
IMDZ
$6.74M 0.88%
5,185,383
+527,030
+11% +$916K
FWP
36
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$6.61M 0.86%
1,211,440
-3,264
-0.3% -$32.9K
SPRO icon
37
Spero Therapeutics
SPRO
$68.9M
$5.18M 0.68%
843,146
-644,942
-43% -$5.22M
CTIC
38
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$5.08M 0.66%
6,929,690
– –
KALV
39
DELISTED
KalVista Pharmaceuticals
KALV
$4.99M 0.65%
252,693
-356,321
-59% -$7.16M
ALBO
40
DELISTED
Albireo Pharma Inc
ALBO
$4.92M 0.64%
200,500
-18,300
-8% -$484K
PHXM
41
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$4.23M 0.55%
62,500
– –
PRNB
42
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$4.01M 0.52%
146,300
-93,700
-39% -$2.41M
OMED
43
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$3.02M 0.39%
4,042,989
– –
CFRX
44
DELISTED
ContraFect Corporation
CFRX
$2.9M 0.38%
2,374
-1,974
-45% -$3.13M
MACK
45
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$2.79M 0.36%
917,579
-493,978
-35% -$1.71M
ALPN
46
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.37M 0.31%
643,059
– –
SURF
47
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.92M 0.25%
451,850
+91,632
+25% +$708K
FRTX
48
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.52M 0.2%
4,082
-148
-3% -$58.1K
GNCA
49
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.47M 0.19%
639,307
-18,818
-3% -$93.6K
EPIX
50
DELISTED
ESSA Pharma
EPIX
$1.22M 0.16%
580,368
+3,597
+0.6% +$10.5K
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2018 Portfolio in Review

As of Q4 2018, BVF Inc held 58 positions worth $765M, down 33% from $1.14B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

BVF Inc withdrew a net $25.7M in Q4 2018, closing 3 positions and reducing 25 holdings. Its most notable exit was TESARO, Inc., an estimated $5.46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 85% a quarter earlier.

Against the trend, BVF Inc opened a new position in Eiger BioPharmaceuticals, Inc. worth $6.86M.

  • BVF Inc's largest Q4 2018 buy was Eiger BioPharmaceuticals, Inc.: 22,500 shares worth $6.86M.
  • BVF Inc added most to Arcus Biosciences in Q4 2018, an estimated $15.8M increase.
  • BVF Inc's biggest Q4 2018 reduction was Ionis Pharmaceuticals, cutting an estimated $26M.
  • BVF Inc fully exited TESARO, Inc. in Q4 2018, selling an estimated $5.46M.
  • BVF Inc's ten largest holdings make up 53% of its $765M portfolio in Q4 2018.
  • BVF Inc opened 1 new position and closed 3 in Q4 2018.
  • BVF Inc's portfolio value fell 33% quarter-over-quarter to $765M.

Based on BVF Inc's 13F filing for Q4 2018, filed 14 Feb 2019.